By contrast, MASLD and ALD, against which RSPO3, LGR4/5 and their downstream target β-catenin protect35,39, represent the commonest forms of CLD and liver fibrosis in patients. Here, LGR4 is linked to metabolic dysfunction-associated steatotic liver disease.